메뉴 건너뛰기




Volumn 140, Issue 2, 2013, Pages 219-232

A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer

Author keywords

Biomarker; Breast cancer; Resistance; Tamoxifen

Indexed keywords

TAMOXIFEN; TUMOR MARKER; 1-(ALPHA-PYRIDINE)-2-PROPANOL; AMINO ACID TRANSPORTER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MAPT PROTEIN, HUMAN; PYRIDINE DERIVATIVE; TAU PROTEIN;

EID: 84881480448     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2622-y     Document Type: Review
Times cited : (165)

References (99)
  • 1
    • 33847793068 scopus 로고    scopus 로고
    • Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial
    • 17312304 10.1093/jnci/djk049 1:CAS:528:DC%2BD2sXjsVeitrs%3D
    • Cuzick J, Forbes JF, Sestak I, et al. (2007) Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272-282
    • (2007) J Natl Cancer Inst , vol.99 , pp. 272-282
    • Cuzick, J.1    Forbes, J.F.2    Sestak, I.3
  • 2
    • 85203363507 scopus 로고    scopus 로고
    • Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
    • 21802721 1:STN:280:DC%2BC3Mjpt1yltg%3D%3D
    • Davies C, Godwin J, Gray R, et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784
    • (2011) Lancet , vol.378 , pp. 771-784
    • Davies, C.1    Godwin, J.2    Gray, R.3
  • 3
    • 0035884430 scopus 로고    scopus 로고
    • Tamoxifen for patients with estrogen receptor-negative breast cancer
    • 11560981 1:CAS:528:DC%2BD3MXnsVKqtrY%3D
    • Swain SM (2001) Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clin Oncol 19:93S-97S
    • (2001) J Clin Oncol , vol.19
    • Swain, S.M.1
  • 4
    • 0032537396 scopus 로고    scopus 로고
    • Tamoxifen for early breast cancer: An overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group 10.1016/S0140-6736(97) 11423-4
    • Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467
    • (1998) Lancet , vol.351 , pp. 1451-1467
  • 5
    • 0038102395 scopus 로고    scopus 로고
    • Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status
    • 12752643 10.1046/j.1524-4741.2003.09325.x
    • Layfield LJ, Goldstein N, Perkinson KR, Proia AD (2003) Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 9:257-259
    • (2003) Breast J , vol.9 , pp. 257-259
    • Layfield, L.J.1    Goldstein, N.2    Perkinson, K.R.3    Proia, A.D.4
  • 6
    • 84864037760 scopus 로고    scopus 로고
    • RecurrenceOnline: An online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data
    • 21773767 10.1007/s10549-011-1676-y 1:CAS:528:DC%2BC38XmtFWhu7o%3D
    • Gyorffy B, Benke Z, Lanczky A, et al. (2012) RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 132:1025-1034
    • (2012) Breast Cancer Res Treat , vol.132 , pp. 1025-1034
    • Gyorffy, B.1    Benke, Z.2    Lanczky, A.3
  • 7
    • 77950691476 scopus 로고    scopus 로고
    • Combinatorial biomarker expression in breast cancer
    • 20107892 10.1007/s10549-010-0746-x 1:CAS:528:DC%2BC3cXjtlahur4%3D
    • Rakha EA, Reis-Filho JS, Ellis IO (2010) Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 120:293-308
    • (2010) Breast Cancer Res Treat , vol.120 , pp. 293-308
    • Rakha, E.A.1    Reis-Filho, J.S.2    Ellis, I.O.3
  • 8
    • 34248214791 scopus 로고    scopus 로고
    • Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients
    • 17239243 10.1186/bcr1639
    • Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6
    • (2007) Breast Cancer Res , vol.9 , pp. 6
    • Dunnwald, L.K.1    Rossing, M.A.2    Li, C.I.3
  • 9
    • 70349929431 scopus 로고    scopus 로고
    • Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
    • 19809024 10.1001/jama.2009.1420 1:CAS:528:DC%2BD1MXht1CksrjO
    • Schroth W, Goetz MP, Hamann U, et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436
    • (2009) JAMA , vol.302 , pp. 1429-1436
    • Schroth, W.1    Goetz, M.P.2    Hamann, U.3
  • 10
    • 79551604866 scopus 로고    scopus 로고
    • Pharmacogenetics of endocrine therapy for breast cancer
    • 21226615 10.1146/annurev-med-070909-182545 1:CAS:528:DC%2BC3MXivVWhtLk%3D
    • Higgins MJ, Stearns V (2011) Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 62:281-293
    • (2011) Annu Rev Med , vol.62 , pp. 281-293
    • Higgins, M.J.1    Stearns, V.2
  • 11
    • 67650333853 scopus 로고    scopus 로고
    • American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
    • 19470930 10.1200/JCO.2008.20.5179 1:CAS:528:DC%2BD1MXhtFWitbrI
    • Visvanathan K, Chlebowski RT, Hurley P, et al. (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258
    • (2009) J Clin Oncol , vol.27 , pp. 3235-3258
    • Visvanathan, K.1    Chlebowski, R.T.2    Hurley, P.3
  • 12
    • 77649170234 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
    • 21603045
    • Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 3:e123-e130
    • (2009) Open Med , vol.3
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 13
    • 70449553671 scopus 로고    scopus 로고
    • Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients
    • 19052860 10.1007/s10549-008-0242-8
    • Gyorffy B, Schafer R (2009) Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat 118:433-441
    • (2009) Breast Cancer Res Treat , vol.118 , pp. 433-441
    • Gyorffy, B.1    Schafer, R.2
  • 14
    • 66249093500 scopus 로고    scopus 로고
    • Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples
    • 19461970 10.1371/journal.pone.0005645
    • Gyorffy B, Molnar B, Lage H, et al. (2009) Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE 4:e5645
    • (2009) PLoS ONE , vol.4 , pp. 5645
    • Gyorffy, B.1    Molnar, B.2    Lage, H.3
  • 15
    • 83455219407 scopus 로고    scopus 로고
    • Jetset: Selecting the optimal microarray probe set to represent a gene
    • 22172014 10.1186/1471-2105-12-474
    • Li Q, Birkbak NJ, Gyorffy B, et al. (2011) Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 12:474
    • (2011) BMC Bioinformatics , vol.12 , pp. 474
    • Li, Q.1    Birkbak, N.J.2    Gyorffy, B.3
  • 16
    • 84861527388 scopus 로고    scopus 로고
    • The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    • 22522925 1:CAS:528:DC%2BC38XlslSnsL8%3D
    • Curtis C, Shah SP, Chin SF, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352
    • (2012) Nature , vol.486 , pp. 346-352
    • Curtis, C.1    Shah, S.P.2    Chin, S.F.3
  • 17
    • 34548561818 scopus 로고    scopus 로고
    • Beadarray: R classes and methods for Illumina bead-based data
    • 17586828 10.1093/bioinformatics/btm311 1:CAS:528:DC%2BD2sXhtVWqtrzL
    • Dunning MJ, Smith ML, Ritchie ME, Tavare S (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23:2183-2184
    • (2007) Bioinformatics , vol.23 , pp. 2183-2184
    • Dunning, M.J.1    Smith, M.L.2    Ritchie, M.E.3    Tavare, S.4
  • 18
    • 0037316303 scopus 로고    scopus 로고
    • A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
    • 12538238 10.1093/bioinformatics/19.2.185 1:CAS:528:DC%2BD3sXitlCnsL4%3D
    • Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193
    • (2003) Bioinformatics , vol.19 , pp. 185-193
    • Bolstad, B.M.1    Irizarry, R.A.2    Astrand, M.3    Speed, T.P.4
  • 19
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumours
    • 10.1038/nature11412 1:CAS:528:DC%2BC38XhtlyltrvN
    • Koboldt DC, Fulton RS, McLellan MD, et al. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
    • (2012) Nature , vol.490 , pp. 61-70
    • Koboldt, D.C.1    Fulton, R.S.2    McLellan, M.D.3
  • 20
    • 79961232797 scopus 로고    scopus 로고
    • The split-apply-combine strategy for data analysis
    • Wickham H (2011) The split-apply-combine strategy for data analysis. J Stat Softw 40:1-29
    • (2011) J Stat Softw , vol.40 , pp. 1-29
    • Wickham, H.1
  • 21
    • 79151483638 scopus 로고    scopus 로고
    • An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
    • 20020197 10.1007/s10549-009-0674-9
    • Gyorffy B, Lanczky A, Eklund AC, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123:725-731
    • (2010) Breast Cancer Res Treat , vol.123 , pp. 725-731
    • Gyorffy, B.1    Lanczky, A.2    Eklund, A.C.3
  • 22
    • 19044384381 scopus 로고    scopus 로고
    • The problem of multiple testing and solutions for genome-wide studies
    • 15853065
    • Gyorffy B, Gyorffy A, Tulassay Z (2005) The problem of multiple testing and solutions for genome-wide studies. Orv Hetil 146:559-563
    • (2005) Orv Hetil , vol.146 , pp. 559-563
    • Gyorffy, B.1    Gyorffy, A.2    Tulassay, Z.3
  • 23
    • 69249137029 scopus 로고    scopus 로고
    • Biological determinants of endocrine resistance in breast cancer
    • 19701242 10.1038/nrc2713 1:CAS:528:DC%2BD1MXhtVegtrzL
    • Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631-643
    • (2009) Nat Rev Cancer , vol.9 , pp. 631-643
    • Musgrove, E.A.1    Sutherland, R.L.2
  • 24
    • 84871773274 scopus 로고    scopus 로고
    • Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study
    • 23045591 10.1200/JCO.2012.42.8896 1:CAS:528:DC%2BC3sXhsFemu70%3D
    • Bartlett JM, Bloom KJ, Piper T, et al. (2012) Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol 30:4477-4484
    • (2012) J Clin Oncol , vol.30 , pp. 4477-4484
    • Bartlett, J.M.1    Bloom, K.J.2    Piper, T.3
  • 25
    • 33746006844 scopus 로고    scopus 로고
    • Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
    • 16809728 10.1200/JCO.2006.05.6564 1:CAS:528:DC%2BD28XnslKhsrc%3D
    • Ring BZ, Seitz RS, Beck R, et al. (2006) Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24:3039-3047
    • (2006) J Clin Oncol , vol.24 , pp. 3039-3047
    • Ring, B.Z.1    Seitz, R.S.2    Beck, R.3
  • 26
    • 78650914558 scopus 로고    scopus 로고
    • Tubulin-independent tau in Alzheimer's disease and cancer: Implications for disease pathogenesis and treatment
    • 20678073 10.2174/156720510793611637 1:CAS:528:DC%2BC3MXis1Onsw%3D%3D
    • Souter S, Lee G (2010) Tubulin-independent tau in Alzheimer's disease and cancer: implications for disease pathogenesis and treatment. Curr Alzheimer Res 7:697-707
    • (2010) Curr Alzheimer Res , vol.7 , pp. 697-707
    • Souter, S.1    Lee, G.2
  • 27
    • 78149478027 scopus 로고    scopus 로고
    • The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
    • 20579400 10.1186/bcr2598
    • Ikeda H, Taira N, Hara F, et al. (2010) The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 12:R43
    • (2010) Breast Cancer Res , vol.12 , pp. 43
    • Ikeda, H.1    Taira, N.2    Hara, F.3
  • 28
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumours
    • Cancer Genome Atlas Network 10.1038/nature11412
    • Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
    • (2012) Nature , vol.490 , pp. 61-70
  • 29
    • 33750328319 scopus 로고    scopus 로고
    • HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition
    • 17018609 10.1158/0008-5472.CAN-05-4470 1:CAS:528:DC%2BD28XhtVamsrfP
    • Wu X, Chen H, Parker B, et al. (2006) HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 66:9527-9534
    • (2006) Cancer Res , vol.66 , pp. 9527-9534
    • Wu, X.1    Chen, H.2    Parker, B.3
  • 30
    • 33847713655 scopus 로고    scopus 로고
    • A role for the HOXB7 homeodomain protein in DNA repair
    • 17308091 10.1158/0008-5472.CAN-06-4283 1:CAS:528:DC%2BD2sXhvVWqs7c%3D
    • Rubin E, Wu X, Zhu T, et al. (2007) A role for the HOXB7 homeodomain protein in DNA repair. Cancer Res 67:1527-1535
    • (2007) Cancer Res , vol.67 , pp. 1527-1535
    • Rubin, E.1    Wu, X.2    Zhu, T.3
  • 31
    • 84863115448 scopus 로고    scopus 로고
    • The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway
    • 21690342 10.1073/pnas.1018859108 1:CAS:528:DC%2BC38Xjs1Wms7Y%3D
    • Jin K, Kong X, Shah T, et al. (2012) The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci USA 109:2736-2741
    • (2012) Proc Natl Acad Sci USA , vol.109 , pp. 2736-2741
    • Jin, K.1    Kong, X.2    Shah, T.3
  • 32
    • 80052572689 scopus 로고    scopus 로고
    • Estrogen receptor beta causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2
    • 21120602 10.1007/s10549-010-1273-5 1:CAS:528:DC%2BC3MXhtFGitb3L
    • Paruthiyil S, Cvoro A, Tagliaferri M, et al. (2011) Estrogen receptor beta causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat 129:777-784
    • (2011) Breast Cancer Res Treat , vol.129 , pp. 777-784
    • Paruthiyil, S.1    Cvoro, A.2    Tagliaferri, M.3
  • 33
    • 0032940738 scopus 로고    scopus 로고
    • Endocrine response and resistance in breast cancer: A role for the transcription factor Fos
    • 9988233 10.1002/(SICI)1097-0215(19990219)84:1<54: AID-IJC11>3.0. CO;2-X 1:STN:280:DyaK1M7ktVOgsA%3D%3D
    • Gee JM, Willsher PC, Kenny FS, et al. (1999) Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. Int J Cancer 84:54-61
    • (1999) Int J Cancer , vol.84 , pp. 54-61
    • Gee, J.M.1    Willsher, P.C.2    Kenny, F.S.3
  • 34
    • 84857377978 scopus 로고    scopus 로고
    • Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen
    • 21482774 10.1073/pnas.1018872108 1:CAS:528:DC%2BC38Xjs1Wms7k%3D
    • Mendes-Pereira AM, Sims D, Dexter T, et al. (2012) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 109:2730-2735
    • (2012) Proc Natl Acad Sci USA , vol.109 , pp. 2730-2735
    • Mendes-Pereira, A.M.1    Sims, D.2    Dexter, T.3
  • 35
    • 28744459050 scopus 로고    scopus 로고
    • Resistance to endocrine therapy in breast cancer
    • 16273353 10.1007/s00280-005-0099-z
    • Kurebayashi J (2005) Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 56(Suppl 1):39-46
    • (2005) Cancer Chemother Pharmacol , vol.56 , Issue.SUPPL. 1 , pp. 39-46
    • Kurebayashi, J.1
  • 36
    • 17844398046 scopus 로고    scopus 로고
    • Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    • 15753463 10.1200/JCO.2005.01.172 1:CAS:528:DC%2BD2MXjvVyktL8%3D
    • Gutierrez MC, Detre S, Johnston S, et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476
    • (2005) J Clin Oncol , vol.23 , pp. 2469-2476
    • Gutierrez, M.C.1    Detre, S.2    Johnston, S.3
  • 37
    • 57749195712 scopus 로고    scopus 로고
    • RNA-Seq: A revolutionary tool for transcriptomics
    • 19015660 10.1038/nrg2484 1:CAS:528:DC%2BD1cXhsFWis7bL
    • Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57-63
    • (2009) Nat Rev Genet , vol.10 , pp. 57-63
    • Wang, Z.1    Gerstein, M.2    Snyder, M.3
  • 38
    • 84857536692 scopus 로고    scopus 로고
    • Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer
    • 22291083 10.1200/JCO.2011.38.9619 1:CAS:528:DC%2BC38Xnt1ygsr0%3D
    • Harbeck N, Rody A (2012) Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. J Clin Oncol 30:686-689
    • (2012) J Clin Oncol , vol.30 , pp. 686-689
    • Harbeck, N.1    Rody, A.2
  • 39
    • 84881478312 scopus 로고    scopus 로고
    • ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer
    • abstr 1002
    • Bouzyk M, Gray KP, Regan MM, Pagani O, et al. (2011) ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. J Clin Oncol 29(suppl 27: abstr 1002)
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 27
    • Bouzyk, M.1    Gray, K.P.2    Regan, M.M.3    Pagani, O.4
  • 40
    • 0029848604 scopus 로고    scopus 로고
    • A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis
    • 8910964 10.1002/(SICI)1097-0258(19961030)15:20<2203: AID-SIM357>3.0.CO;2-G 1:STN:280:DyaK2s%2FmslGlug%3D%3D
    • Faraggi D, Simon R (1996) A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med 15:2203-2213
    • (1996) Stat Med , vol.15 , pp. 2203-2213
    • Faraggi, D.1    Simon, R.2
  • 41
    • 70349582555 scopus 로고    scopus 로고
    • Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
    • 18830816 10.1007/s10549-008-0200-5 1:CAS:528:DC%2BD1MXhtFGmtr3E
    • Dignam JJ, Dukic V, Anderson SJ, et al. (2009) Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 116:595-602
    • (2009) Breast Cancer Res Treat , vol.116 , pp. 595-602
    • Dignam, J.J.1    Dukic, V.2    Anderson, S.J.3
  • 42
    • 0029759541 scopus 로고    scopus 로고
    • Annual hazard rates of recurrence for breast cancer after primary therapy
    • 8874335 1:STN:280:DyaK2s%2FivVehsw%3D%3D
    • Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746
    • (1996) J Clin Oncol , vol.14 , pp. 2738-2746
    • Saphner, T.1    Tormey, D.C.2    Gray, R.3
  • 43
    • 33144462268 scopus 로고    scopus 로고
    • Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
    • 16478745 10.1093/jnci/djj052 1:CAS:528:DC%2BD28Xhs1Skt74%3D
    • Sotiriou C, Wirapati P, Loi S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272
    • (2006) J Natl Cancer Inst , vol.98 , pp. 262-272
    • Sotiriou, C.1    Wirapati, P.2    Loi, S.3
  • 44
    • 26444546442 scopus 로고    scopus 로고
    • An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
    • 16141321 10.1073/pnas.0506230102 1:CAS:528:DC%2BD2MXhtVygtr7I
    • Miller LD, Smeds J, George J, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550-13555
    • (2005) Proc Natl Acad Sci USA , vol.102 , pp. 13550-13555
    • Miller, L.D.1    Smeds, J.2    George, J.3
  • 45
    • 34247145491 scopus 로고    scopus 로고
    • Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    • 17401012 10.1200/JCO.2006.07.1522 1:CAS:528:DC%2BD2sXkvFyms7w%3D
    • Loi S, Haibe-Kains B, Desmedt C, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246
    • (2007) J Clin Oncol , vol.25 , pp. 1239-1246
    • Loi, S.1    Haibe-Kains, B.2    Desmedt, C.3
  • 46
    • 67649230285 scopus 로고    scopus 로고
    • The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy
    • 18821012 10.1007/s10549-008-0183-2 1:CAS:528:DC%2BD1MXntF2nt78%3D
    • Zhang Y, Sieuwerts AM, McGreevy M, et al. (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116:303-309
    • (2009) Breast Cancer Res Treat , vol.116 , pp. 303-309
    • Zhang, Y.1    Sieuwerts, A.M.2    McGreevy, M.3
  • 47
    • 44949121510 scopus 로고    scopus 로고
    • Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    • 18498629 10.1186/1471-2164-9-239
    • Loi S, Haibe-Kains B, Desmedt C, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239
    • (2008) BMC Genomics , vol.9 , pp. 239
    • Loi, S.1    Haibe-Kains, B.2    Desmedt, C.3
  • 48
    • 68149147400 scopus 로고    scopus 로고
    • The gene expression grade index: A potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
    • 19573224 10.1186/1755-8794-2-40
    • Desmedt C, Giobbie-Hurder A, Neven P, et al. (2009) The gene expression grade index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics 2:40
    • (2009) BMC Med Genomics , vol.2 , pp. 40
    • Desmedt, C.1    Giobbie-Hurder, A.2    Neven, P.3
  • 49
    • 77957935139 scopus 로고    scopus 로고
    • Genomic index of sensitivity to endocrine therapy for breast cancer
    • 20697068 10.1200/JCO.2010.28.4273
    • Symmans WF, Hatzis C, Sotiriou C, et al. (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:4111-4119
    • (2010) J Clin Oncol , vol.28 , pp. 4111-4119
    • Symmans, W.F.1    Hatzis, C.2    Sotiriou, C.3
  • 50
    • 76349095348 scopus 로고    scopus 로고
    • Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer
    • 20098429 10.1038/nm.2090
    • Li Y, Zou L, Li Q, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16:214-218
    • (2010) Nat Med , vol.16 , pp. 214-218
    • Li, Y.1    Zou, L.2    Li, Q.3
  • 51
    • 84881476871 scopus 로고    scopus 로고
    • Use of progesterone receptor (PR) expression to predict benefit from prolonged adjuvant tamoxifen (TAM) in breast cancer: Results of a biomarker study from the TAM01 randomized Trial
    • abstr 536
    • Mathieue M (2009) Use of progesterone receptor (PR) expression to predict benefit from prolonged adjuvant tamoxifen (TAM) in breast cancer: Results of a biomarker study from the TAM01 randomized Trial. J Clin Oncol 27(15 suppl: abstr 536)
    • (2009) J Clin Oncol , vol.27 , Issue.15 SUPPL.
    • Mathieue, M.1
  • 52
    • 84881479317 scopus 로고    scopus 로고
    • Automated quantification methods improve the accuracy of pr as an independent prognostic factor in tamoxifen treated breast cancer patients
    • Klimowicz A (2011) Automated quantification methods improve the accuracy of pr as an independent prognostic factor in tamoxifen treated breast cancer patients. SABCS (abstr P5-11-11)
    • (2011) SABCS (Abstr P5-11-11)
    • Klimowicz, A.1
  • 53
    • 26044478813 scopus 로고    scopus 로고
    • Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
    • 16000581 10.1158/1078-0432.CCR-05-0196 1:CAS:528:DC%2BD2MXlvVGgs74%3D
    • Tovey S, Dunne B, Witton CJ, et al. (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11:4835-4842
    • (2005) Clin Cancer Res , vol.11 , pp. 4835-4842
    • Tovey, S.1    Dunne, B.2    Witton, C.J.3
  • 54
    • 84881475329 scopus 로고    scopus 로고
    • Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays
    • abstr 560
    • Zoubir M (2008) Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays. J Clin Oncol 26(20 suppl: abstr 560)
    • (2008) J Clin Oncol , vol.26 , Issue.20 SUPPL.
    • Zoubir, M.1
  • 55
    • 78650892625 scopus 로고    scopus 로고
    • Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
    • 20615243 10.1186/bcr2604
    • Bartlett JM, Thomas J, Ross DT, et al. (2010) Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 12:R47
    • (2010) Breast Cancer Res , vol.12 , pp. 47
    • Bartlett, J.M.1    Thomas, J.2    Ross, D.T.3
  • 56
    • 84881481463 scopus 로고    scopus 로고
    • Loss of B-cell translocation gene 2 in estrogen receptor-positive breast cancer and tamoxifen resistance
    • abstr 63
    • Hayashida T (2011) Loss of B-cell translocation gene 2 in estrogen receptor-positive breast cancer and tamoxifen resistance. J Clin Oncol 29(suppl 27: abstr 63)
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 27
    • Hayashida, T.1
  • 57
    • 84881478903 scopus 로고    scopus 로고
    • The importance of CXCL10 and CXCR3-A in breast cancer
    • (abstr P1-06-06)
    • Hilborn E (2011) The importance of CXCL10 and CXCR3-A in breast cancer. SABCS (abstr P1-06-06)
    • (2011) SABCS
    • Hilborn, E.1
  • 60
    • 33947411267 scopus 로고    scopus 로고
    • Bad expression predicts outcome in patients treated with tamoxifen
    • 17004114 10.1007/s10549-006-9323-8 1:CAS:528:DC%2BD2sXjt1Kqurg%3D
    • Cannings E, Kirkegaard T, Tovey SM, et al. (2007) Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 102:173-179
    • (2007) Breast Cancer Res Treat , vol.102 , pp. 173-179
    • Cannings, E.1    Kirkegaard, T.2    Tovey, S.M.3
  • 61
    • 58149263068 scopus 로고    scopus 로고
    • BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
    • 19066611 10.1038/sj.bjc.6604809 1:CAS:528:DC%2BD1MXjt1Shtg%3D%3D
    • Millar EK, Anderson LR, McNeil CM, et al. (2009) BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer 100:123-133
    • (2009) Br J Cancer , vol.100 , pp. 123-133
    • Millar, E.K.1    Anderson, L.R.2    McNeil, C.M.3
  • 62
    • 84881477337 scopus 로고    scopus 로고
    • Gene expression profile that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: A DBCG study
    • (abstr P4-09-04)
    • Lyng M (2012) Gene expression profile that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. SABCS (abstr P4-09-04)
    • (2012) SABCS
    • Lyng, M.1
  • 63
    • 84881475191 scopus 로고    scopus 로고
    • Bcl-2 as a prognostic marker in breast cancer patients receiving endocrine therapy
    • Larsen M (2011) Bcl-2 as a prognostic marker in breast cancer patients receiving endocrine therapy. SABCS (abstr P2-12-08)
    • (2011) SABCS (Abstr P2-12-08)
    • Larsen, M.1
  • 64
    • 84881477316 scopus 로고    scopus 로고
    • Cyclin D1 and its prognostic value in planning of endocrine therapy for women of postmenopausal age with breast cancer
    • Skvortsov V (2011) Cyclin D1 and its prognostic value in planning of endocrine therapy for women of postmenopausal age with breast cancer. SABCS (abstr P4-01-22)
    • (2011) SABCS (Abstr P4-01-22)
    • Skvortsov, V.1
  • 65
    • 32144462322 scopus 로고    scopus 로고
    • CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases
    • 16739331 1:CAS:528:DC%2BD28Xhs1ahs7o%3D
    • Surowiak P, Materna V, Paluchowski P, et al. (2006) CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res 26:629-634
    • (2006) Anticancer Res , vol.26 , pp. 629-634
    • Surowiak, P.1    Materna, V.2    Paluchowski, P.3
  • 66
    • 84881476560 scopus 로고    scopus 로고
    • Loss of e-cadherin expression in clinical breast cancer is associated with an adverse outcome on tamoxifen
    • Hiscox S (2011) Loss of e-cadherin expression in clinical breast cancer is associated with an adverse outcome on tamoxifen. SABCS (abstr P1-06-18)
    • (2011) SABCS (Abstr P1-06-18)
    • Hiscox, S.1
  • 67
    • 38549141939 scopus 로고    scopus 로고
    • Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
    • 18242510 10.1016/j.ccr.2008.01.001 1:CAS:528:DC%2BD1cXitFWrs7o%3D
    • Iorns E, Turner NC, Elliott R, et al. (2008) Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13:91-104
    • (2008) Cancer Cell , vol.13 , pp. 91-104
    • Iorns, E.1    Turner, N.C.2    Elliott, R.3
  • 68
    • 84881478337 scopus 로고    scopus 로고
    • Predictive biomarkers of endocrine therapy (ET) for stage IV breast cancer (BC)
    • abstr e11090
    • Shimizu C (2011) Predictive biomarkers of endocrine therapy (ET) for stage IV breast cancer (BC). J Clin Oncol 29(suppl 27: abstr e11090)
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 27
    • Shimizu, C.1
  • 70
    • 84860462662 scopus 로고    scopus 로고
    • Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial
    • 21986093 10.1093/annonc/mdr438 1:STN:280:DC%2BC38zmtlKkug%3D%3D
    • Ejlertsen B, Aldridge J, Nielsen KV, et al. (2012) Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol 23:1138-1144
    • (2012) Ann Oncol , vol.23 , pp. 1138-1144
    • Ejlertsen, B.1    Aldridge, J.2    Nielsen, K.V.3
  • 71
    • 79958182017 scopus 로고    scopus 로고
    • Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
    • 20556506 10.1007/s10549-010-0984-y 1:CAS:528:DC%2BC3MXls1Cit7w%3D
    • Nielsen KV, Ejlertsen B, Muller S, et al. (2011) Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 127:345-355
    • (2011) Breast Cancer Res Treat , vol.127 , pp. 345-355
    • Nielsen, K.V.1    Ejlertsen, B.2    Muller, S.3
  • 72
    • 84963885795 scopus 로고    scopus 로고
    • Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial
    • abstr 1050
    • Singer C (2012) Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial. J Clin Oncol 30(suppl: abstr 1050)
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Singer, C.1
  • 73
    • 84881481498 scopus 로고    scopus 로고
    • The effect of HER2 expression on luminal A breast tumors
    • Ellsworth R (2012) The effect of HER2 expression on luminal A breast tumors. SABCS (abstr PD02-02)
    • (2012) SABCS (Abstr PD02-02)
    • Ellsworth, R.1
  • 74
    • 78650987804 scopus 로고    scopus 로고
    • Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
    • 20306127 10.1007/s10549-010-0836-9 1:CAS:528:DC%2BC3cXhsFCqt7zN
    • Reijm EA, Jansen MP, Ruigrok-Ritstier K, et al. (2011) Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat 125:387-394
    • (2011) Breast Cancer Res Treat , vol.125 , pp. 387-394
    • Reijm, E.A.1    Jansen, M.P.2    Ruigrok-Ritstier, K.3
  • 76
    • 84881478593 scopus 로고    scopus 로고
    • Proteomic screening of FFPE tissue identifies FKBP4 as an independent prognostic factor in hormone receptor positive breast cancers
    • Hu J (2012) Proteomic screening of FFPE tissue identifies FKBP4 as an independent prognostic factor in hormone receptor positive breast cancers. SABCS (abstr P6-07-17)
    • (2012) SABCS (Abstr P6-07-17)
    • Hu, J.1
  • 77
    • 84863223625 scopus 로고    scopus 로고
    • Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients
    • 22476979 10.1007/s12672-012-0111-0 1:CAS:528:DC%2BC38XpsFWktbg%3D
    • Ijichi N, Shigekawa T, Ikeda K, et al. (2012) Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer 3:147-159
    • (2012) Horm Cancer , vol.3 , pp. 147-159
    • Ijichi, N.1    Shigekawa, T.2    Ikeda, K.3
  • 78
    • 84881474753 scopus 로고    scopus 로고
    • The role of RIP140 and FOXA1 in breast cancer endocrine sensitivity and resistance
    • Harada-Shoji N (2012) The role of RIP140 and FOXA1 in breast cancer endocrine sensitivity and resistance. SABCS (abstr P6-04-16)
    • (2012) SABCS (Abstr P6-04-16)
    • Harada-Shoji, N.1
  • 79
    • 77951537595 scopus 로고    scopus 로고
    • Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer
    • 12223126 10.1186/bcr456
    • Reimer T, Koczan D, Muller H, et al. (2002) Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer. Breast Cancer Res 4:R9
    • (2002) Breast Cancer Res , vol.4 , pp. 9
    • Reimer, T.1    Koczan, D.2    Muller, H.3
  • 80
    • 84881480614 scopus 로고    scopus 로고
    • G protein-coupled estrogen receptor 1 positively correlates with estrogen receptor a expression and increased distant disease-free survival of breast cancer patients
    • Leeb-Lundberg F (2011) G protein-coupled estrogen receptor 1 positively correlates with estrogen receptor a expression and increased distant disease-free survival of breast cancer patients. SABCS (abstr P4-09-02)
    • (2011) SABCS (Abstr P4-09-02)
    • Leeb-Lundberg, F.1
  • 81
    • 84881477838 scopus 로고    scopus 로고
    • Neutralizing antibody to human GP88 (progranulin) restores sensitivity to tamoxifen and inhibits breast tumor growth in mouse xenografts
    • Serrero G (2012) Neutralizing antibody to human GP88 (progranulin) restores sensitivity to tamoxifen and inhibits breast tumor growth in mouse xenografts. SABCS (abstr P6-04-19)
    • (2012) SABCS (Abstr P6-04-19)
    • Serrero, G.1
  • 82
    • 27644597480 scopus 로고    scopus 로고
    • A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
    • 16000569 10.1158/1078-0432.CCR-04-2569
    • De Laurentiis M, Arpino G, Massarelli E, et al. (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748
    • (2005) Clin Cancer Res , vol.11 , pp. 4741-4748
    • De Laurentiis, M.1    Arpino, G.2    Massarelli, E.3
  • 83
    • 2942578063 scopus 로고    scopus 로고
    • A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
    • 15193263 10.1016/j.ccr.2004.05.015 1:CAS:528:DC%2BD2cXltlGgsLs%3D
    • Ma XJ, Wang Z, Ryan PD, et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616
    • (2004) Cancer Cell , vol.5 , pp. 607-616
    • Ma, X.J.1    Wang, Z.2    Ryan, P.D.3
  • 84
    • 84866703356 scopus 로고    scopus 로고
    • Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer
    • 23029174 10.1371/journal.pone.0045669 1:CAS:528:DC%2BC38XhsVGht7jI
    • Busch S, Ryden L, Stal O, et al. (2012) Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. PLoS ONE 7:e45669
    • (2012) PLoS ONE , vol.7 , pp. 45669
    • Busch, S.1    Ryden, L.2    Stal, O.3
  • 85
    • 78149348826 scopus 로고    scopus 로고
    • High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients
    • 20889557 10.2353/ajpath.2010.100220 1:CAS:528:DC%2BC3cXhsFWhu7fI
    • Watson C, Long JS, Orange C, et al. (2010) High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 177:2205-2215
    • (2010) Am J Pathol , vol.177 , pp. 2205-2215
    • Watson, C.1    Long, J.S.2    Orange, C.3
  • 86
    • 33646429471 scopus 로고    scopus 로고
    • Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen
    • 16603346 10.1016/j.ejca.2006.01.028 1:CAS:528:DC%2BD28Xks1ertbg%3D
    • Bergqvist J, Elmberger G, Ohd J, et al. (2006) Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer 42:1104-1112
    • (2006) Eur J Cancer , vol.42 , pp. 1104-1112
    • Bergqvist, J.1    Elmberger, G.2    Ohd, J.3
  • 87
    • 84881481455 scopus 로고    scopus 로고
    • Molecular tumor characteristics influence adjuvant endocrine treatment outcome
    • Bianchini G (2011) Molecular tumor characteristics influence adjuvant endocrine treatment outcome. SABCS (abstr S1-7)
    • (2011) SABCS (Abstr S1-7)
    • Bianchini, G.1
  • 88
    • 27144482128 scopus 로고    scopus 로고
    • Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance
    • 16136485 1:CAS:528:DC%2BD2MXht1OksLvM
    • Surowiak P, Matkowski R, Materna V, et al. (2005) Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance. Histol Histopathol 20:1037-1044
    • (2005) Histol Histopathol , vol.20 , pp. 1037-1044
    • Surowiak, P.1    Matkowski, R.2    Materna, V.3
  • 89
    • 77949519750 scopus 로고    scopus 로고
    • AIB1 is a predictive factor for tamoxifen response in premenopausal women
    • 19628566 10.1093/annonc/mdp293 1:STN:280:DC%2BC3c%2FmsVOmsQ%3D%3D
    • Alkner S, Bendahl PO, Grabau D, et al. (2010) AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 21:238-244
    • (2010) Ann Oncol , vol.21 , pp. 238-244
    • Alkner, S.1    Bendahl, P.O.2    Grabau, D.3
  • 90
    • 43149090547 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer
    • 17636398 10.1007/s10549-007-9645-1 1:CAS:528:DC%2BD1cXlsV2ntr0%3D
    • Dihge L, Bendahl PO, Grabau D, et al. (2008) Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 109:255-262
    • (2008) Breast Cancer Res Treat , vol.109 , pp. 255-262
    • Dihge, L.1    Bendahl, P.O.2    Grabau, D.3
  • 91
    • 84872002796 scopus 로고    scopus 로고
    • SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERalpha transcriptional activity
    • 23117886 10.1158/0008-5472.CAN-12-2241 1:CAS:528:DC%2BC3sXjs1Wkuw%3D%3D
    • Zhang L, Gong C, Lau SL, et al. (2013) SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERalpha transcriptional activity. Cancer Res 73:246-255
    • (2013) Cancer Res , vol.73 , pp. 246-255
    • Zhang, L.1    Gong, C.2    Lau, S.L.3
  • 92
    • 35549002845 scopus 로고    scopus 로고
    • Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer
    • 17486065 10.1038/sj.onc.1210506 1:CAS:528:DC%2BD2sXht1Wgt7rJ
    • Bostner J, Ahnstrom Waltersson M, Fornander T, et al. (2007) Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26:6997-7005
    • (2007) Oncogene , vol.26 , pp. 6997-7005
    • Bostner, J.1    Ahnstrom Waltersson, M.2    Fornander, T.3
  • 93
    • 84881474865 scopus 로고    scopus 로고
    • Global analysis of breast cancer metastasis suggests cellular reprogramming is central to the endocrine resistant phenotype
    • Bolger J (2012) Global analysis of breast cancer metastasis suggests cellular reprogramming is central to the endocrine resistant phenotype. SABCS (abstr P6-04-01)
    • (2012) SABCS (Abstr P6-04-01)
    • Bolger, J.1
  • 94
    • 0029021196 scopus 로고
    • Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
    • 7563153 10.1093/jnci/87.10.751 1:STN:280:DyaK28%2FgtFehtA%3D%3D
    • Foekens JA, Look MP, Peters HA, et al. (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87:751-756
    • (1995) J Natl Cancer Inst , vol.87 , pp. 751-756
    • Foekens, J.A.1    Look, M.P.2    Peters, H.A.3
  • 95
    • 84881475801 scopus 로고    scopus 로고
    • PTEN mRNA positivity using in situ measurements is associated with better outcome in Tamoxifen treated breast cancer patients
    • Schalper KA (2012) PTEN mRNA positivity using in situ measurements is associated with better outcome in Tamoxifen treated breast cancer patients. SABCS (abstr P3-06-25)
    • (2012) SABCS (Abstr P3-06-25)
    • Schalper, K.A.1
  • 96
    • 63149111430 scopus 로고    scopus 로고
    • Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients
    • 19228750 10.1158/1078-0432.CCR-07-4967 1:CAS:528:DC%2BD1MXitVOktLc%3D
    • McGlynn LM, Kirkegaard T, Edwards J, et al. (2009) Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 15:1487-1495
    • (2009) Clin Cancer Res , vol.15 , pp. 1487-1495
    • McGlynn, L.M.1    Kirkegaard, T.2    Edwards, J.3
  • 97
    • 82855167015 scopus 로고    scopus 로고
    • Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer
    • abstr 560
    • Basik M (2011) Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer. J Clin Oncol 29(suppl: abstr 560)
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Basik, M.1
  • 98
    • 84857048945 scopus 로고    scopus 로고
    • Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment
    • 22134837 10.1007/s00432-011-1096-8 1:CAS:528:DC%2BC38XpslOlug%3D%3D
    • Elsberger B, Paravasthu DM, Tovey SM, Edwards J (2012) Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. J Cancer Res Clin Oncol 138:327-332
    • (2012) J Cancer Res Clin Oncol , vol.138 , pp. 327-332
    • Elsberger, B.1    Paravasthu, D.M.2    Tovey, S.M.3    Edwards, J.4
  • 99
    • 84881481560 scopus 로고    scopus 로고
    • Wnt5a is a prognostic biomarker in estrogen receptor-positive premenopausal breast cancer
    • Sand-Dejmek J (2011) Wnt5a is a prognostic biomarker in estrogen receptor-positive premenopausal breast cancer. SABCS (abstr P5-01-02)
    • (2011) SABCS (Abstr P5-01-02)
    • Sand-Dejmek, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.